

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Standard Technology Appraisal

## Lifileucel for previously treated unresectable or metastatic melanoma ID3863

## Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Iovance Biotherapeutics (Lifileucel)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Cancer52</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• Melanoma Fund</li> <li>• Melanoma UK</li> <li>• OcuMel UK</li> <li>• Skcin- Karen Clifford Skin Cancer Charity</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association of Dermatologists</li> <li>• British Association of Skin Cancer Specialist Nurses</li> <li>• British Association of Surgical Oncology</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Skin Foundation</li> <li>• Cancer Research UK</li> <li>• Melanoma Focus</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Amgen (talimogene laherparepvec)</li> <li>• Bristol-Myers Squibb (ipilimumab, nivolumab)</li> <li>• Merck Sharp &amp; Dohme (pembrolizumab)</li> <li>• Novartis (dabrafenib, trametinib)</li> <li>• Pierre Fabre (binimetinib, encorafenib)</li> <li>• Roche (vemurafenib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Skin Group</li> <li>• Dermatrust</li> <li>• Genomics England</li> </ul>

Provisional stakeholder list for the health technology appraisal of lifileucel for previously treated unresectable or metastatic melanoma ID3863

Issue date: August 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

Page 1 of 3

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> <li>• United Kingdom Cutaneous Lymphoma Group</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Skin Cancer Research Fund</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the health technology appraisal of lifileucel for previously treated unresectable or metastatic melanoma ID3863

Issue date: August 2024

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.